Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors
Open Access
- 8 September 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (18) , 6550
Abstract
Imetelstat sodium (GRN163L; hereafter, imetelstat) is a first-in-class telomerase inhibitor that has demonstrated activity in patients with myeloproliferative neoplasms (MPNs). Treatment with imetelstat has been associated with thrombocytopenia and other hematologic adverse effects that were manageable and reversible. Toll-like receptors (TLRs) are proteins that recognize pathogen-associated molecular patterns and stimulate innate immune and pro-apoptotic responses. Because imetelstat is an oligonucleotide, and some oligonucleotides can activate TLRs, we conducted an in vitro study to rule out the possibility of imetelstat-associated thrombocytopenia by off-target effects through activation of TLRs. We used HEK293 cell lines stably co-expressing a human TLR gene and an NFκB-inducible reporter to investigate whether imetelstat can activate TLR signaling. We treated the cells with imetelstat or control oligonucleotides for 20 h, and used absorbance of the culture media to calculate the reporter activity. Treatment with imetelstat within or beyond the clinically relevant concentrations had no stimulatory effect on TLR2, TLR3, TLR4, TLR5, TLR7, or TLR9. This result was not surprising since the structure of imetelstat does not meet the reported minimal structural requirements for TLR9 activation. Furthermore, imetelstat treatment of the MPN cell line HEL did not impact the expression of TLR signaling pathway target genes that are commonly induced by activation of different TLRs, whereas it significantly reduced its target gene hTERT, human telomerase reverse transcriptase, in a dose- and time-dependent manner. Hence, cytopenias, especially thrombocytopenia observed in some patients treated with imetelstat, are not mediated by off-target interactions with TLRs.Keywords
This publication has 26 references indexed in Scilit:
- Gene expression induced by Toll-like receptors in macrophages requires the transcription factor NFAT5Journal of Experimental Medicine, 2012
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytesThrombosis Research, 2010
- Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heartAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivoLeukemia, 2008
- Telomere length of cord blood-derived CD34+ progenitors predicts erythroid proliferative potentialLeukemia, 2007
- Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivoBlood, 2006
- Insights into host responses against pathogens from transcriptional profilingNature Reviews Microbiology, 2005
- Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8Science, 2004
- Telomeres and telomerase in normal and malignant haematopoietic cellsEuropean Journal of Cancer, 1997